Everything below concerns acetylated peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-17. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
=== Other and unspecified disorders of metabolism === 277 Other and unspecified disorders of metabolism 277.0 Cystic fibrosis 277.1 Disorders of porphyrin metabolism Porphyria Acute intermittent porphyria 277.2 Other disorders of purine and pyrimidine metabolism Lesch–Nyhan syndrome Purine nucleoside phosphorylase deficiency Xanthinuria 277.3 Amyloidosis Familial Mediterranean fever 277.4 Hyperbilirubinemia Crigler–Najjar syndrome Gilbert's syndrome 277.5 Mucopolysaccharidosis Hunter syndrome Hurler syndrome Morquio–Brailsford disease Sanfilippo syndrome 277.6 Other deficiencies of circulating enzymes Alpha 1-antitrypsin deficiency Biotinidase deficiency Hereditary angioedema 277.7 Dysmetabolic syndrome X Metabolic syndrome 277.8 Other specified disorders of metabolism 277.81 Primary carnitine deficiency 277.82 Carnitine deficiency due to inborn errors of metabolism 277.83 Iatrogenic carnitine deficiency 277.84 Other secondary carnitine deficiency 277.85 Disorders of fatty acid oxidation metabolism Carnitine palmitoyltransferase I deficiency Carnitine palmitoyltransferase II deficiency Very long-chain acyl-coenzyme A dehydrogenase deficiency Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency Medium-chain acyl-coenzyme A dehydrogenase deficiency 277.86 Disorders of peroxisomal metabolism Zellweger syndrome 277.87 Disorders of mitochondrial metabolism Kearns–Sayre syndrome Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS syndrome) Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE) Myoclonus with epilepsy and with ragged red fibers (MERRF syndrome) Neuropathy, ataxia, and retinitis pigmentosa (NARP syndrome) 277.88 Tumor lysis syndrome 277.89 Other specified disorders of metabolism
Guided bone regeneration (GBR) and guided tissue regeneration (GTR) are dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Guided bone regeneration typically refers to ridge augmentation or bone regenerative procedures; guided tissue regeneration typically refers to regeneration of periodontal attachment.
However, the reduction of seizure threshold could be attributed to tramadol's putative inhibition of GABAA receptors at high doses (significant inhibition at 100 μM). In addition, desmetramadol is a high-affinity ligand of the DOR, and activation of this receptor could be involved in tramadol's ability to provoke seizures in some individuals, as DOR agonists are well known for inducing seizures. Nausea and vomiting caused by tramadol are thought to be due to activation of the 5-HT3 receptor via increased serotonin levels. In accordance, the 5-HT3 receptor antagonist ondansetron can be used to treat tramadol-associated nausea and vomiting. Tramadol and desmetramadol themselves do not bind to the 5-HT3 receptor.
Sources: en.wikipedia.org
== Promoter assays == Reporter genes can be used to assay for the activity of a particular promoter in a cell or organism. In this case there is no separate "gene of interest"; the reporter gene is simply placed under the control of the target promoter and the reporter gene product's activity is quantitatively measured. The results are normally reported relative to the activity under a "consensus" promoter known to induce strong gene expression.
== Further reading == B.L. Karger, 2014, "Separation and Purification: Single-stage versus multistage processes" and "Separation and Purification: Separations Based on Equilibrium", Encyclopædia Britannica, see [1] and [2], accessed 12 May 2014. Gunt Hamburg, 2014, "Thermal Process Engineering: liquid–liquid extraction and solid-liquid extraction", see [3], accessed 12 May 2014. G.W. Stevens, T.C., Lo, & M. H. I. Baird, 2007, "Extraction, liquid–liquid", in Kirk-Othmer Encyclopedia of Chemical Technology, doi:10.1002/0471238961.120917211215.a01.pub2, accessed 12 May 2014. Colin Poole & Michael Cooke, 2000, "Extraction", in Encyclopedia of Separation Science, 10 Vols., ISBN 978-0-12-226770-3, see [4], accessed 12 May 2014. Sikdar, Cole, et al. Aqueous Two-Phase Extractions in Bioseparations: An Assessment. Biotechnology 9:254. 1991 Szlag, Giuliano. A Low-Cost Aqueous Two Phase System for Enzyme Extraction. Biotechnology Techniques 2:4:277. 1988 Dreyer, Kragl. Ionic Liquids for Aqueous Two-Phase Extraction and Stabilization of Enzymes. Biotechnology and Bioengineering. 99:6:1416. 2008 Boland. Aqueous Two-Phase Systems: Methods and Protocols. Pg 259-269 https://web.archive.org/web/20100702074135/http://ull.chemistry.uakron.edu/chemsep/extraction/ Topological Analysis of the Gibbs Energy Function (Liquid-Liquid Equilibrium Correlation Data). Including a Thermodynamic Review and a Graphical User Interface (GUI) for Surfaces/Tie-lines/Hessian matrix analysis - University of Alicante (Reyes-Labarta et al. 2015-18)
Narrated by Tim Pigott-Smith, produced by Patrick Uden, directed by Sheila Hayman, made by Uden Associates 4 September The Tin Snail, about the Citroën 2CV; the 2CV was first introduced in October 1948; André Citroën saw himself as a French Henry Ford, and met American automotive industrialists in October 1931, including Henry Ford at the newly opened Ford Engineering Laboratory; the industrial historian Patrick Fridenson; Citroën lit up the Eiffel Tower in Citroën regalia, for publicity; but although André Citroën followed and admired Henry Ford, Citroën were innovative themselves, on 18 April 1934 the company launched the world's first mass-produced front-wheel drive car, the Citroën Traction Avant, when the company was narrowly avoiding bankruptcy; André Citroën died in 1935 and his company, being heavily in debt, was taken over by Édouard Michelin (brother of André Michelin); Fiat introduced its similar Fiat 500 in 1935, designed by Dante Giacosa; Ferdinand Porsche designed a new mass-produced car with rear air-cooled horizontally-opposed four-cylinder engine; France did not have such a car to Germany, so Citroën developed the Toute Petite Voiture (TPV), a proposal of Pierre Michelin - he brought in André Lefèbvre, who had designed the front-wheel-drive system of the Traction Avant and was a former aircraft engineer of Voisin, and led by Pierre-Jules Boulanger; Lefèbvre came from the aviation industry, and to save weight, made the car out of aluminium; the car had a torsion bar suspension, with eight torsion bars; Flaminio Bertoni, an Italian, was head of exterior design at Citroën, from 1932 to 1964; Carl Olsen, head of Citroën exterior design from 1982 to 1987; Alex Moulton, the Cambridge-educated mechanical engineer, who designed the suspension for the innovative Mini, in the late 1950s; Lucien Gerard, from Talbot, and Walter Becchia, who designed the two-cylinder water-cooled horizontally opposed engine. Narrated by Peter Jones, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 11 September Deep Trouble, about the North Sea oil industry; the beginning of 1986 saw peak production of North Sea oil; finding new oil reserves would be from deeper oil fields, that cost more money to extract; at the same time the oil price plummeted, with over 15,000 job losses in the British oil industry by the end of 1986; Vickers Ltd entered the oil exploration industry; submersible craft were helping exploration of oil, with remotely operated craft becoming important. Narrated by Martin Jarvis, produced by Patrick Uden, directed by Paul Fabricius, made by Uden Associates 18 September What They Don't Tell You When They Sell You a Computer, about professionalism in the computer hardware industry; Eddy Shah from the Today newspaper, and their new unreliable computer system; Brian Wilson of First Computer believed that the computer hardware retailing industry were largely unprofessional unscrupulous cowboys; the National Computing Centre (NCC) was set up by the government in 1966, to provide advice; BP opened its own Microshop, to circumvent the cowboys, and assist with technical jargon, and connecting devices; due to warp-drive technical obsolescence in the 1980s, yesterday's computers rapidly lost all total value; Iain Callaghan, operations director of John Menzies newspaper distribution business, and how computer databases could process newsagents' daily orders much quicker and reliably; Geoff Dalby, head of data at Woolwich Equitable Building Society, which had called off a merger with the Nationwide Building Society, as their computer systems would not work together; greater computer automation of the personal finance industry could lead to much less day-to-day contact with individual customers; David Bailey of Phillips & Drew. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 25 September Precisely in Profit, about manufacturing to exact margins. Produced by Glyn Jones, directed by Eben Wilson, made by Quanta 2 October Now Eat This, about snack foods. Produced by Edward Poulter, directed by Mike Tomlinson, made by London Scientific Films 9 October Growing up with Rockets, a personal, and underreported, view of early elementary rocketry from 1950, starting with captured German V-2 rockets; the former 1970 class of Cocoa Beach High School; failed launches would land in the Banana River; NASA was formed in July 1958, in a coherent response to the Russian launches in 1957; the President visits Cocoa Beach to celebrate the US getting a man to orbit the Earth in February 1962; the nearby Patrick Air Force Base; Syncom 3 was launched on 19 August 1964, the world's first geostationary communication satellite, on a Delta rocket; the minutes leading up to the first launch of STS-1 in April 1981. Directed and a first hand account of Nancy Yasecko, produced by Patrick Uden, made by Uden Associates 16 October Shock Trauma, about the Baltimore Shock Trauma Center (R Adams Cowley Shock Trauma Center). A Canadian production, produced by Patrick Uden, made by National Film Board of Canada and Uden Associates 23 October Drink Drive and Murder; it featured two court cases in the US, where a 33 year old killed a couple in their 20s, and a 17 year old who killed a couple of teenagers, and a Californian drink-drive reform centre; in some US states, if you kill when drunk, the charge is murder. A Canadian production, made by Uden Associates and the National Film Board of Canada 30 October The New Magicians, about film special effects; Gertie the Dinosaur in 1914 and The Sinking of the Lusitania in 1918; the King Kong (1933 film); the 1950s and 1960s saw modest increases in special effects, notably Forbidden Planet in 1956, until 2001: A Space Odyssey was important in 1968; another important film was Star Wars (film) in 1977, along with Close Encounters of the Third Kind, Tron in 1982 and The Last Starfighter in 1984. A Canadian production, produced by Ken McKay, made by TV Ontario 6 November Pioneers of the Future, about the development of microchips, such as Steve Dorsey, who invented the word processor. A Canadian production, produced by Ken McKay, made by Uden Associates and TV Ontario 13 November Skyscraper, about Old Madison Square Gardens and skyscrapers in Chicago and New York; Arthur Nusbaum; architect Stanley Tigerman; the tallest masonry-only building was 16 storeys high; the Great Chicago Fire in October 1871, which allowed different, and stronger, structures of building to be built instead; the 1902 Flatiron Building; architect Jack Hartray; mechanical engineer George Strakosch; the 1908 600-feet Singer Building; the 1912 800-feet Woolworth Building; the 1915 Equitable Building (Manhattan); the 1930 900-feet Chrysler Building; the 1931 1250-feet Empire State Building; mechanical engineer David Stillman; structural engineer Charles Thornton; architect Robert Sobel; structural engineer Leslie E. Robertson; civil engineer Alan Garnett Davenport of the University of Western Ontario; architect Bruce Graham; architect Harry Weese; architect Moshe Safdie. Narrated by William Woollard, produced by Nicola Glucksmann, directed by Karl Sabbagh, made by InCA
Sources: en.wikipedia.org
=== Pregnancy and lactation === Its use in pregnant and lactating women is advised against, although the available evidence suggests it is unlikely to cause negative effects on fetal development. The lack of evidence from human studies, however, means it is currently impossible to rule out any risk to the fetus and it is known to cross the placenta. Doxepin is secreted in breast milk and neonatal cases of respiratory depression in association with maternal doxepin use have been reported.
Before the widespread use of a vaccine against measles, rates of disease were so high that infection was felt to be "as inevitable as death and taxes." Reported cases of measles in the United States fell from hundreds of thousands to tens of thousands per year following introduction of the vaccine in 1963. Increasing uptake of the vaccine following outbreaks in 1971, and 1977, brought this down to thousands of cases per year in the 1980s. An outbreak of almost 30,000 cases in 1990 led to a renewed push for vaccination and the addition of a second vaccine to the recommended schedule. Fewer than 200 cases have been reported in the US each year between 1997 and 2013, and the disease is no longer considered endemic there. The benefit of measles vaccination in preventing illness, disability, and death has been well documented. The first 20 years of licensed measles vaccination in the US prevented an estimated 52 million cases of the disease, 17,400 cases of intellectual disability, and 5,200 deaths. During 1999–2004, a strategy led by the World Health Organization and UNICEF led to improvements in measles vaccination coverage that averted an estimated 1.4 million measles deaths worldwide. Between 2000 and 2018, measles vaccination resulted in a 73% decrease in deaths from the disease. Measles is common in many areas of the world. Although it was declared eliminated from the US in 2000, high rates of vaccination and good communication with people who refuse vaccination are needed to prevent outbreaks and sustain the elimination of measles in the US.
Lys arylation Similar to cysteine, lysine N-arylation could be achieved through Pd OACs with different dialkylbiaryl phosphine ligands. Due to weaker nucleophilicity and slower reductive elimination rate compared to cysteine, the selection of supporting ligands is shown to be critical. The bulky BrettPhos and t-BuBrettPhos ligands in conjunction with mildly basic sodium phenoxide have been used as the strategy to functionalize lysines on peptide substrates. The reaction happens in mild conditions and is selective over most other nucleophilic amino acid residues.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.